Difference between revisions of "Team:CPU CHINA"

Line 13: Line 13:
  
 
}
 
}
−
h1,h2,h3,h4{
+
h1,h2,h4{
 
font-family: "Century Gothic";
 
font-family: "Century Gothic";
 +
}
 +
h3{
 +
font-family: "Times New Roman";
 +
font-size: 40px;
 +
}
 +
 +
.body-container h5 {
 +
font-family: "Comic Sans MS";
 +
font-size: 60px;
 +
text-align: center;
 
}
 
}
 
</style>
 
</style>
Line 24: Line 34:
 
             <img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300">
 
             <img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300">
 
             </center>
 
             </center>
−
             <h3>Our HEAD-Treg</h3>
+
             <h5>Our HEAD-Treg</h5>
 
             <center>
 
             <center>
−
             <video src="https://static.igem.org/mediawiki/2017/1/14/T--CPU_CHINA--mainpagevideo.mp4" controls="controls" class="video" width = "80%"></video>
+
             <video src="https://static.igem.org/mediawiki/2017/1/14/T--CPU_CHINA--mainpagevideo.mp4" controls="controls" class="video" width = "60%"></video>
 
             </center>
 
             </center>
−
             <p class="body-title" style="padding-top:100px">Description</p>
+
             <h3>Description</h3>
−
            <div class="content" style="margin-top:60px">
+
 
 
                 <h4><br>Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease.
 
                 <h4><br>Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease.
 
                 <br>It is of great essence to develop a kind of novel cell-targeted therapy for RA because there is no radical cure
 
                 <br>It is of great essence to develop a kind of novel cell-targeted therapy for RA because there is no radical cure
Line 36: Line 46:
 
                     inflammatory environment, which enables them to play their role of immunosuppression in lesions more
 
                     inflammatory environment, which enables them to play their role of immunosuppression in lesions more
 
                     efficiently and more stably. These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4>
 
                     efficiently and more stably. These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4>
−
            </div>
+
 
 
         </div>
 
         </div>
 
</body>
 
</body>

Revision as of 10:53, 1 November 2017

Our HEAD-Treg

Description


Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease.
It is of great essence to develop a kind of novel cell-targeted therapy for RA because there is no radical cure for RA for the time being. To solve the problems existing in the current treatment of RA, we design and build a brand new immunotherapy. FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified utilizing a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated with RA.
Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the inflammatory environment, which enables them to play their role of immunosuppression in lesions more efficiently and more stably. These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect.